Articles from Valion Bio, Inc.
Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement
By Valion Bio, Inc. · Via ACCESS Newswire · August 13, 2026
AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall
By Valion Bio, Inc. · Via ACCESS Newswire · August 12, 2026
